Scaffold Hopping in De Novo Design. Ligand Generation in the Absence of Receptor Information

Journal of Medicinal Chemistry

Volumn 47, Issue 3, 2004, Pages 493-496

  Lloyd, David G ^a   Buenemann, Christoph L ^a   Todorov, Nikolay P ^a   Manallack, David T ^a   Dean, Philip M ^a  

^a De Novo Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; LIGAND; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; PSEUDORECEPTOR; RECEPTOR; STEROID; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CHEMICAL STRUCTURE; CHEMOTYPE; CLASSIFICATION; COMPUTER AIDED DESIGN; COMPUTER PROGRAM; CONFORMATION; DRUG DESIGN; DRUG RESEARCH; INFORMATION; LIGAND BINDING; PHARMACOPHORE; RECEPTOR BINDING; SCAFFOLD HOPPING; SYNTHESIS; TECHNIQUE;

BENZENE DERIVATIVES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING SITES; DRUG DESIGN; LIGANDS; MODELS, MOLECULAR; RECEPTORS, ESTROGEN;

EID: 1642458726     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034222u     Document Type: Article

References (30)

1. Stahl, M.; Todorov, N. P.; James, T.; Mauser, H.; Boehm, H. J.; Dean, P. M. A validation study on the practical use of automated de novo design. J. Comput. Aided Mol. Des. 2002, 16 (7), 459-478.
2. Schneider, G.; Lee, M. L.; Stahl, M.; Schneider, P. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J. Comput. Aided Mol. Des. 2000, 14 (5), 487-494.
3. Mancera, R. L. De novo ligand design with explicit water molecules: an application to bacterial neuraminidase. J. Comput. Aided Mol. Des. 2002, 16 (7), 479-499.
4. Takano, Y.; Koizumi, M.; Takarada, R.; Takimoto Kamimura, M.; Czerminski, R.; Koike, T. Computer-aided design of a factor Xa inhibitor by using MCSS functionality maps and a CAVEAT linker search. J. Mol. Graph. Model. 2003, 22 (2), 105-114.
5. Schmidt, J. M.; Mercure, J.; Tremblay, G. B.; Page, M.; Kalbakji, A.; Feher, M.; Dunn-Dufault, R.; Peter, M. G.; Redden, P. R. De novo design, synthesis, and evaluation of novel nonsteroidal phenanthrene ligands for the estrogen receptor. J. Med. Chem. 2003, 46 (8), 1408-1418.
6. Waszkowycz, B. Structure-based approaches to drug design and virtual screening. Curr. Opin. Drug Discovery Dev. 2002, 5 (3), 407-413.
7. Bogacewicz, R.; Trylska, J.; Geller, M. Ligand design package (Ludi- -MSI) applied to known inhibitors of the HIV-1 protease. Test of performance. Acta Pol. Pharm. 2000, 57 Suppl, 25-28.
8. Kuhn, P.; Wilson, K.; Patch, M. G.; Stevens, R. C. The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr. Opin. Chem. Biol. 2002, 6 (5), 704-710.
9. Hicks, S.; Assefa, H.; Sindelar, R. Computer-aided design of enzyme inhibitors: recent studies. Curr. Opin. Drug Discuss. Dev. 1999, 2, 223-234.
10. Klebe, G. Recent developments in structure-based drug design. J. Mol. Med. 2000, 78, 269-281.
11. De Lucca, G. V.; Erickson-Viitanen, S.; Lam, P. Y. S. Cyclic HIV protease inhibitors capable of displacing the active site structural water molecule, Drug Discovery Today 1997, 2 (1), 6-18.
12. von Itzstein, M.; Wu, W.-Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colmant, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-423.
13. Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T-H.; Hutchinson, T. L.; Elliott, A. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Larver, G. W.; Montgomery, J. A. BCX-1812 (RWJ-270201): Discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43, 3482-3486.
14. Wang, G. T.; Chen, Y.; Wang, S.; Gentles, R.; Sowin, T.; Kati, W.; Muchmore, S.; Giranda, V.; Stewart, K.; Sham, H.; Kempf, D.; Laver, W. G. Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. J. Med. Chem. 2001, 44, 1192-1201.
15. Chand, P.; Kotian, P. L.; Deghani, A.; El-Kattan, Y.; Lin, T. H.; Hutchinson, T. L.; Babu, Y. S.; Bantia, S.; Elliott, A. J.; Montgomery, J. A. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. J. Med. Chem. 2001, 44, 4379-4392.
16. De Esch, I. J.; Mills, J. E.; Perkins, T. D.; Romeo, G.; Hoffmann, M.; Wieland, K.; Leurs, R.; Menge, W. M.; Nederkoorn, P. H.; Dean, P. M.; Timmerman, H. Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE. J. Med. Chem. 2001, 44 (11), 1666-1674.
17. Bureau, R.; Daveu, C.; Lemaitre, S.; Dauphin, F.; Landelle, H.; Lancelot, J. C.; Rault, S. Molecular design based on 3D-pharmacophore. Application to 5-HT4 receptor. J. Chem. Inf. Comput. Sci. 2002, 42 (4), 962-967.
18. Waszkowycz, B.; Clark, D. E.; Frenkel, D.; Li, J.; Murray, C. W.; Robson, B.; Westhead, D. R. PRO_LIGAND: an approach to de novo molecular design. 2. Design of novel molecules from molecular field analysis (MFA) models and pharmacophores. J. Med. Chem. 1994, 37 (23), 3994-4002.
19. Manetti, F.; Forli, S.; Maccari, L.; Corelli, F.; Botta, M. 3D QSAR studies of the interaction between beta-tubulin and microtubule stabilizing antimitotic agents (MSAA). A combined pharmacophore generation and pseudoreceptor modeling approach applied to taxanes and epothilones. Farmaco. 2003, 58 (5), 357-361.
20. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. " Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. Angew. Chem. Int. Ed. Engl. 1999, 38 (19), 2894-2896.
21. Mills, J. E.; Dean, P. M. Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. J. Comput. Aided Mol. Des. 1996, 10 (6), 607-622.
22. Derwent World Drug Alerts, 2002, Derwent Information, London.
23. Lloyd, D. G.; Meegan, M. J. Recent advances in estrogen receptor antagonists, Drugs 2000, 6 (3) 632-642.
24. Meegan, M. J.; Lloyd, D. G. Advances in the science of estrogen receptor modulation. Curr. Med. Chem. 2003, 10, 181-210.
25. Lloyd, D. G.; Perry, N. P.; Todorov, N. P. T.; Alberts, I. L.; De Esch, I. J. P. Virtual site model derivation and application to lead identification. In Proceedings of 224th American Chemical SocietyCS National Meeting, Boston, MA, Aug 18-22, 2002. http://www.lib.uchicago.edu/cinf/224nm/presentations/224nm015.pdf.
26. Perry, N. P.; Lloyd, D. G.; Todorov, N. P.; Alberts, I. L. The use of ligand-based site models in virtual high-throughput screening. In QSAR Proceedings 2002: Euro QSAR 2002: Designing drugs and crop protectants; Blackwell Publishing Ltd.: Malden, MA, 2003..
27. Van Den Bemd, G. J.; Kuiper, G. G.; Pols, H. A.; Van Leeuwen, J. P. Distinct effects on the conformation of estrogen receptor alpha and beta by both the antiestrogens ICI 164, 384 and ICI 182, 780 leading to opposite effects on receptor stability. Biochem. Biophys. Res. Commun. 1999, 261 (1), 1-5.
28. Pike, A. C.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A. G.; Li, Y. L.; Gustafsson, J. A.; Carlquist, M. Structural insights into the mode of action of a pure antiestrogen. Structure 2001, 9 (2), 145-153.
29. Meegan, M. J.; Hughes, R. B.; Lloyd, D. G.; Williams, D. C.; Zisterer, D. M. Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells. J. Med. Chem. 2001, 44 (7), 1072-1084.
30. Guner, O. F. History and evolution of the pharmacophore concept in computer-aided drug design. Curr. Top. Med. Chem. 2002, 2 (12), 1321-1332.